hotspot -WSS

hotspot

author：comprehensive 2025-09-27 11:58:13 - browse：111

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： How one medical school became remarkably diverse

WSS

Criminal prosecution for violating HIPAA: an emerging threat

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

HIV vaccine remains elusive. Immunologists keep trying new ideas

The cancer drug shortage isn’t new — and neither are the solutions

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Anxious about a speech? A startup wants you to pop a minty cardiac drug

hotspot

hotspot

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Supreme Court strikes down use of affirmative action

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Bright Health sells Medicare Advantage business to Molina

Bright Health sells Medicare Advantage business to Molina

Supreme Court strikes down use of affirmative action

New air purifier tech could be key to improving indoor air quality

The cancer drug shortage isn’t new — and neither are the solutions

When prostate cancer spreads, where it goes matters

hotspot

Helping hospitals and community health centers plan for resilience

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Peter Hotez and the public health issue of online harassment

As demand for Covid shots wanes, Moderna seeks its next success

hotspot

knowledge

hotspot

knowledge